A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders - Wikidata - awgldk - TriplyDB

A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders

A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders

http://www.wikidata.org/entity/Q37265471

about

IL-21 Signaling in Immunity Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models Lymphoma: immune evasion strategies Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies Common gamma chain cytokines in combinatorial immune strategies against cancer Interleukin-21: a double-edged sword with therapeutic potential.IL-21: a pleiotropic cytokine with potential applications in oncology.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.IL-21 and T Cell Differentiation: Consider the Context.Interleukin 21 - its potential role in the therapy of B-cell lymphomas.Modeling the chronic lymphocytic leukemia microenvironment in vitro.Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia.

P2860

Q26766361-B63379C4-AB9A-44A4-8E58-4AA21E31B9E8 Q26796316-2C5A1C0F-DF52-4FA8-B73F-0DA10E67D6D1 Q26993238-3BD02EFF-9AC6-4B3C-AEE7-5DD60D3D9EB4 Q27312250-EDC78616-68BA-45E7-BD79-6298BF35241D Q28080705-8D7E0473-BC13-457A-99D7-BA5739AFB048 Q35056309-88D641F7-CEE2-41F7-8419-0DD9CCE3BC1F Q35163167-F6FC87F9-C412-42E4-AA7D-CCA3294716BB Q35754594-820ADD8D-3977-4B02-A43B-6FF074C56231 Q36091283-5E884D80-0E84-4AB2-A50C-31976EC334BB Q36334833-F3F40EF3-29AE-4F9C-91FB-29FA704F9F8B Q36455872-3947721A-DC9F-4353-A610-AA40391238E4 Q38206058-8F0029F1-83BD-4C83-BD83-71921463D243 Q38471387-A5629E40-9363-4063-9B25-8FC631B2CD5E Q38807514-2E9E3F0C-D95D-435D-AC5D-66464DA233DF Q38831202-F39BC3A5-3F3D-4C32-9103-D53DA492AD41 Q38889721-83BAB6A4-2788-442B-B859-935BABE23F98 Q38894228-7F760AD8-3741-499D-B192-B50E879CFF5C Q38984569-D2E4AED3-AD98-435D-85E8-4D78353D01EA Q49036164-53D12545-2B2D-4E8E-ABFA-997438C4AAE9 Q50958025-A7DBD79C-F832-43AD-B8F7-9B1E34801141

P2860

A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders

http://www.wikidata.org/entity/Q37265471

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A phase I dose-finding trial o ...... lymphoproliferative disorders

@en

A phase I dose-finding trial o ...... lymphoproliferative disorders.

@nl

type

label

A phase I dose-finding trial o ...... lymphoproliferative disorders

@en

A phase I dose-finding trial o ...... lymphoproliferative disorders.

@nl

prefLabel

A phase I dose-finding trial o ...... lymphoproliferative disorders

@en

A phase I dose-finding trial o ...... lymphoproliferative disorders.

@nl

P1433

Q37265471-9151CCA7-F57E-4D1C-9B1A-39515E0DEBDC

P1476

Q37265471-5DD28D1D-56D9-4AEB-BFA8-7C617B105BB6

P2093

Q37265471-29F023B1-DB9D-465F-A9E0-BF0C75D934CA

Q37265471-48B5A5BC-614F-4F9B-BB70-488B7E233314

Q37265471-6934780D-9413-4ABB-9DF7-2CCA36A8B595

Q37265471-8D7233D2-7872-409F-9B69-AE8FC4FBA2CD

Q37265471-E3EAAF85-FF50-4771-BB9E-BEACB2BB5B0B

Q37265471-E80CB7A7-FDEF-43C4-976F-4E3578456D89

Q37265471-E9BB30FD-CB52-44A6-B051-12100E7AF0CA

P2860

Q37265471-09BA5A3C-14F4-4B69-AE2C-6062171E1759

Q37265471-1FAC853E-3259-4A76-999E-A097DDF42BD8

Q37265471-23905734-A55C-4B48-B163-E4E6CCA279CD

Q37265471-27F9E2C5-5446-4154-8D88-95C527BC4799

Q37265471-32D43857-1438-4185-B679-64876F60E3EF

Q37265471-356D844B-2EA3-4D6B-83E5-26B8B380F607

Q37265471-36B582A2-569E-4165-BE87-4F317AA1BA9D

Q37265471-3838F8AF-26DD-4D55-8705-6D4FAC299059

Q37265471-38904F1E-845E-4D9D-B3E0-6A06C539286C

Q37265471-3A00B658-D091-4E83-862E-19D6F323BE4A

P304

Q37265471-979358AA-A64D-44D3-8902-48CF21F1EAAD

P31

Q37265471-28A2C339-546A-4E5E-BC40-C95C606F85E6

P356

Q37265471-A30A6EDF-5D4A-456F-81E8-1D17A86F2B03

P407

Q37265471-B044AF52-90ED-44C3-A6F2-FF767149BBEF

P433

Q37265471-33827AE1-C17A-4DE3-8025-940C89D447DD

P478

Q37265471-EF14A37D-EFD4-4CD5-8678-EB69ABE3C4F9

P50

Q37265471-3D737825-CC5A-45E3-8C17-F5DF4DEB585B

P577

Q37265471-7C590543-BDD8-4C66-86BB-55394477E45E

P698

Q37265471-62460890-6315-4143-AB6F-C8646302CC95

P921

Q37265471-764ce7a2-f257-41cc-90a2-cfac182af609

Q37265471-F1F90502-09CB-475F-A857-BE5A49D5374C

P932

Q37265471-1B636A44-0BC1-45C2-96D8-0EF8615166AA

P356

1078-0432.CCR-12-0456

P1433

Clinical Cancer Research

P1476

A phase I dose-finding trial o ...... lymphoproliferative disorders

@en

P2093

David J Andorsky

http://www.w3.org/2001/XMLSchema#string

Janet Kramer

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

John M Timmerman

http://www.w3.org/2001/XMLSchema#string

Naomi Hunder

http://www.w3.org/2001/XMLSchema#string

Natarajan Muthusamy

http://www.w3.org/2001/XMLSchema#string

Reiko E Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors

Interleukin-21 activates human natural killer cells and modulates their surface receptor expression

Rituximab: mechanism of action

IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21

IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

Antigenic modulation and rituximab resistance.

P304

5752-5760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-0456

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22893631

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

5027960

http://www.w3.org/2001/XMLSchema#string